Analytical Data
-
Gene name
HLA-A*02:01&B2M&MART-1(ELAGIGILTV) Monomer
- Application
-
Alternative Names
MART1; LB39-AA; SK29-AA; Melan-A; MLANA
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)&ELAGIGILTV
-
Molecular Weight
53-63 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01 is one of the most prevalent human leukocyte antigen (HLA) class I molecules, playing a crucial role in the immune response by presenting peptide antigens to CD8+ T cells. The B2M (beta-2-microglobulin) protein is essential for the stability and surface expression of HLA class I molecules. MART-1 (melanoma antigen recognized by T cells), particularly the peptide ELAGIGILTV, is a tumor-associated antigen frequently expressed in melanoma, making it a significant target in cancer immunotherapy. The reconstitution of the HLA-A*02:01/B2M/MART-1 (ELAGIGILTV) monomeric recombinant protein allows researchers to study the structural and functional properties of this complex in detail. This protein is pivotal for examining T-cell receptor interactions, understanding the mechanisms of immune recognition in cancer, and developing targeted therapeutic strategies. By characterizing this monomeric form, researchers aim to enhance vaccine designs and improve T-cell based immunotherapies, ultimately contributing to more effective treatments for melanoma and possibly other malignancies.
